Shuang Liu1, Yang Cao1, Tian Du2, Yuxiang Zhi3. 1. Department of Allergy & Clinical Immunology, National Clinical Research Center for Immunologic Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China; School of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China; Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. 3. Department of Allergy & Clinical Immunology, National Clinical Research Center for Immunologic Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: yuxiang_zhi@126.com.
Abstract
BACKGROUND: The impact of asthma on COVID-19 remains largely unknown. OBJECTIVE: To investigate the asthma prevalence among COVID-19 patients and compare outcomes between asthma and non-asthma patients. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Biorxiv and Medrxiv for studies reporting asthma prevalence in general COVID-19 patients or comparing outcomes between asthma and non-asthma patients, and excluded duplicate publications, reviews, editorials, comments, single case reports or small case series (<10 cases). We determined the pooled estimates of effect using random-effect-model. RESULTS: Based on 131 studies (410382 patients), we found great variability in the prevalence of comorbid asthma among COVID-19 patients in different countries or regions ranging from 1.1% to 16.9%. No significant difference in asthma prevalence was found between hospitalized and non-hospitalized (RR: 1.15, 95% confidence interval: 0.92-1.43), severe and non-severe (RR: 1.21, 95% confidence interval: 0.92-1.57), ICU and non-ICU (RR: 1.19, 95% confidence interval: 0.92-1.54,), dead and survived (RR: 0.90, 95% confidence interval: 0.73-1.11), intubated/mechanically ventilated and non-intubated/mechanically ventilated (RR: 0.91, 95% confidence interval: 0.71-1.17) COVID-19 patients. Asthmatic patients have a lower risk of death compared with non-asthmatic patients (RR: 0.65, 95% confidence interval: 0.43-0.98). Asthma is not associated with higher risk of intubation or mechanical ventilation (RR: 1.03, 95% confidence interval: 0.72-1.46). CONCLUSIONS: There is great variability in asthma prevalence among COVID-19 patients in different countries or regions. Asthma is not associated with higher COVID-19 severity or worse prognosis, and asthmatic patients are found to have lower risk of death compared with non-asthmatic patients.
BACKGROUND: The impact of asthma on COVID-19 remains largely unknown. OBJECTIVE: To investigate the asthma prevalence among COVID-19patients and compare outcomes between asthma and non-asthmapatients. METHODS: In this systematic review and meta-analysis, we searched PubMed, Embase, Web of Science, Biorxiv and Medrxiv for studies reporting asthma prevalence in general COVID-19patients or comparing outcomes between asthma and non-asthmapatients, and excluded duplicate publications, reviews, editorials, comments, single case reports or small case series (<10 cases). We determined the pooled estimates of effect using random-effect-model. RESULTS: Based on 131 studies (410382 patients), we found great variability in the prevalence of comorbid asthma among COVID-19patients in different countries or regions ranging from 1.1% to 16.9%. No significant difference in asthma prevalence was found between hospitalized and non-hospitalized (RR: 1.15, 95% confidence interval: 0.92-1.43), severe and non-severe (RR: 1.21, 95% confidence interval: 0.92-1.57), ICU and non-ICU (RR: 1.19, 95% confidence interval: 0.92-1.54,), dead and survived (RR: 0.90, 95% confidence interval: 0.73-1.11), intubated/mechanically ventilated and non-intubated/mechanically ventilated (RR: 0.91, 95% confidence interval: 0.71-1.17) COVID-19patients. Asthmatic patients have a lower risk of death compared with non-asthmatic patients (RR: 0.65, 95% confidence interval: 0.43-0.98). Asthma is not associated with higher risk of intubation or mechanical ventilation (RR: 1.03, 95% confidence interval: 0.72-1.46). CONCLUSIONS: There is great variability in asthma prevalence among COVID-19patients in different countries or regions. Asthma is not associated with higher COVID-19 severity or worse prognosis, and asthmatic patients are found to have lower risk of death compared with non-asthmatic patients.
Authors: Miguel Angel Diaz; Nelly Catalan-Caceres; Thais C Beauperthuy; Carlos Domingo; Ethel Ibañez; Carmen Morata; Alfredo De Diego Journal: J Asthma Allergy Date: 2022-06-08
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333